vs
CONSUMER PORTFOLIO SERVICES, INC.（CPSS）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是CONSUMER PORTFOLIO SERVICES, INC.的1.2倍（$127.1M vs $109.4M），再鼎医药同比增速更快（17.1% vs 3.9%），CONSUMER PORTFOLIO SERVICES, INC.自由现金流更多（$288.3M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 9.2%）
Consumer Portfolio Services, Inc.是总部位于美国的专业金融公司，主要面向信用记录有限或信用评分不佳的消费者，与各类汽车经销商合作，提供新车及二手车购买的间接汽车贷款融资及贷后管理服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CPSS vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.2倍
$109.4M
营收增速更快
ZLAB
高出13.2%
3.9%
自由现金流更多
CPSS
多$315.0M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
9.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $109.4M | $127.1M |
| 净利润 | $5.0M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 6.6% | -54.6% |
| 净利率 | 4.6% | — |
| 营收同比 | 3.9% | 17.1% |
| 净利润同比 | -3.2% | — |
| 每股收益（稀释后） | $0.21 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPSSZLAB
| Q4 25 | $109.4M | $127.1M | ||
| Q3 25 | $108.4M | $115.4M | ||
| Q2 25 | $109.8M | $109.1M | ||
| Q1 25 | $106.9M | $105.7M | ||
| Q4 24 | $105.3M | $108.5M | ||
| Q3 24 | $100.6M | $101.8M | ||
| Q2 24 | $95.9M | $100.1M | ||
| Q1 24 | $91.7M | $87.1M |
净利润CPSSZLAB
| Q4 25 | $5.0M | — | ||
| Q3 25 | $4.9M | $-36.0M | ||
| Q2 25 | $4.8M | $-40.7M | ||
| Q1 25 | $4.7M | $-48.4M | ||
| Q4 24 | $5.1M | — | ||
| Q3 24 | $4.8M | $-41.7M | ||
| Q2 24 | $4.7M | $-80.3M | ||
| Q1 24 | $4.6M | $-53.5M |
毛利率CPSSZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率CPSSZLAB
| Q4 25 | 6.6% | -54.6% | ||
| Q3 25 | 6.5% | -42.3% | ||
| Q2 25 | 6.3% | -50.3% | ||
| Q1 25 | 6.4% | -53.3% | ||
| Q4 24 | 7.0% | -62.6% | ||
| Q3 24 | 6.8% | -66.6% | ||
| Q2 24 | 7.0% | -76.0% | ||
| Q1 24 | 7.1% | -80.7% |
净利率CPSSZLAB
| Q4 25 | 4.6% | — | ||
| Q3 25 | 4.5% | -31.2% | ||
| Q2 25 | 4.4% | -37.3% | ||
| Q1 25 | 4.4% | -45.8% | ||
| Q4 24 | 4.9% | — | ||
| Q3 24 | 4.8% | -40.9% | ||
| Q2 24 | 4.9% | -80.2% | ||
| Q1 24 | 5.0% | -61.4% |
每股收益（稀释后）CPSSZLAB
| Q4 25 | $0.21 | $-0.05 | ||
| Q3 25 | $0.20 | $-0.03 | ||
| Q2 25 | $0.20 | $-0.04 | ||
| Q1 25 | $0.19 | $-0.04 | ||
| Q4 24 | $0.21 | $-0.09 | ||
| Q3 24 | $0.20 | $-0.04 | ||
| Q2 24 | $0.19 | $-0.08 | ||
| Q1 24 | $0.19 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.3M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $309.5M | $715.5M |
| 总资产 | $3.9B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CPSSZLAB
| Q4 25 | $6.3M | $689.6M | ||
| Q3 25 | $9.4M | $717.2M | ||
| Q2 25 | $15.8M | $732.2M | ||
| Q1 25 | $29.8M | $757.3M | ||
| Q4 24 | $11.7M | $779.7M | ||
| Q3 24 | $8.1M | $616.1M | ||
| Q2 24 | $9.8M | $630.0M | ||
| Q1 24 | $13.2M | $650.8M |
股东权益CPSSZLAB
| Q4 25 | $309.5M | $715.5M | ||
| Q3 25 | $307.6M | $759.9M | ||
| Q2 25 | $303.1M | $791.7M | ||
| Q1 25 | $298.4M | $810.8M | ||
| Q4 24 | $292.8M | $840.9M | ||
| Q3 24 | $285.1M | $667.7M | ||
| Q2 24 | $280.3M | $704.2M | ||
| Q1 24 | $279.1M | $762.2M |
总资产CPSSZLAB
| Q4 25 | $3.9B | $1.2B | ||
| Q3 25 | $3.8B | $1.2B | ||
| Q2 25 | $3.8B | $1.2B | ||
| Q1 25 | $3.7B | $1.2B | ||
| Q4 24 | $3.5B | $1.2B | ||
| Q3 24 | $3.5B | $985.3M | ||
| Q2 24 | $3.3B | $987.4M | ||
| Q1 24 | $3.0B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $289.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $288.3M | $-26.7M |
| 自由现金流率自由现金流/营收 | 263.5% | -21.0% |
| 资本支出强度资本支出/营收 | 0.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 58.02× | — |
| 过去12个月自由现金流最近4个季度 | $500.9M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CPSSZLAB
| Q4 25 | $289.0M | $-26.0M | ||
| Q3 25 | $84.9M | $-32.0M | ||
| Q2 25 | $54.5M | $-31.0M | ||
| Q1 25 | $73.9M | $-61.7M | ||
| Q4 24 | $233.8M | $-55.8M | ||
| Q3 24 | $69.8M | $-26.8M | ||
| Q2 24 | $43.3M | $-42.2M | ||
| Q1 24 | $52.7M | $-90.1M |
自由现金流CPSSZLAB
| Q4 25 | $288.3M | $-26.7M | ||
| Q3 25 | $84.9M | $-35.0M | ||
| Q2 25 | $54.3M | $-33.9M | ||
| Q1 25 | $73.4M | $-63.2M | ||
| Q4 24 | $233.3M | $-58.4M | ||
| Q3 24 | $69.7M | $-28.2M | ||
| Q2 24 | $43.1M | $-42.9M | ||
| Q1 24 | $52.6M | $-91.1M |
自由现金流率CPSSZLAB
| Q4 25 | 263.5% | -21.0% | ||
| Q3 25 | 78.3% | -30.4% | ||
| Q2 25 | 49.5% | -31.1% | ||
| Q1 25 | 68.7% | -59.9% | ||
| Q4 24 | 221.6% | -53.8% | ||
| Q3 24 | 69.3% | -27.7% | ||
| Q2 24 | 45.0% | -42.9% | ||
| Q1 24 | 57.3% | -104.5% |
资本支出强度CPSSZLAB
| Q4 25 | 0.6% | 0.5% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.4% | 1.5% | ||
| Q4 24 | 0.4% | 2.4% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 0.2% | 0.7% | ||
| Q1 24 | 0.1% | 1.1% |
现金转化率CPSSZLAB
| Q4 25 | 58.02× | — | ||
| Q3 25 | 17.50× | — | ||
| Q2 25 | 11.35× | — | ||
| Q1 25 | 15.74× | — | ||
| Q4 24 | 45.43× | — | ||
| Q3 24 | 14.55× | — | ||
| Q2 24 | 9.27× | — | ||
| Q1 24 | 11.48× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPSS
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
